BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Jonathan P. Evans, Boleslaw K. Winiarski, Paul A. Sutton, Robert P. Jones, Lorenzo Ressel, Carrie A. Duckworth, D. Mark Pritchard, Zhi-Xiu Lin, Fretwell L. Vicky, Elizabeth M. Tweedle, Eithne Costello, Christopher E. Goldring, Ian M. Copple, B. Kevin Park, Daniel H. Palmer, Neil R. Kitteringham. The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerOncotarget 2018; 9(43): 27104 doi: 10.18632/oncotarget.25497
2
Peng Zhu, Zhi Ye, Dong Guo, Zongping Xiong, Shiqiong Huang, Jun Guo, Wei Zhang, James E. Polli, Honghao Zhou, Qing Li, Yan Shu. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2)Pharmaceutical Research 2018; 35(12) doi: 10.1007/s11095-018-2526-y
3
A.L. Zakharenko, O.A. Luzina, D.N. Sokolov, V.I. Kaledin, V.P. Nikolin, N.A. Popova, J. Patel, O.D. Zakharova, A.A. Chepanova, A. Zafar, J. Reynisson, E. Leung, I.K.H. Leung, K.P. Volcho, N.F. Salakhutdinov, O.I. Lavrik. Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topoteсan on in vivo tumor modelsEuropean Journal of Medicinal Chemistry 2019; 161: 581 doi: 10.1016/j.ejmech.2018.10.055
4
Takeshi Kinoshita, Hajime Higuchi, Ayano- Kabashima-, Gen Sakai, Yasuo Hamamoto, Hiromasa Takaishi, Takanori Kanai. Analysis of Sensitivity and Cell Death Pathways Mediated by Anti-cancer Drugs Using Three-dimensional Culture SystemInternational Journal of Cancer Research 2018; 14(1): 1 doi: 10.3923/ijcr.2018.1.12
5
Carolina de la Guardia, David Stephens, Hang Dang, Mario Quijada, Oleg Larionov, Ricardo Lleonart. Antiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2Molecules 2018; 23(3): 672 doi: 10.3390/molecules23030672
6
Kei Irie, Akira Okada, Yoshio Masuda, Keizo Fukushima, Nobuyuki Sugioka, Chiyuki Okuda, Akito Hata, Reiko Kaji, Yutaka Okada, Nobuyuki Katakami, Shoji Fukushima. Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapyJournal of Oncology Pharmacy Practice 2019; 25(4): 865 doi: 10.1177/1078155218769136
7
Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang. Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12Frontiers of Medicine 2019; 13(1): 83 doi: 10.1007/s11684-019-0682-z
8
Ram P. Das, Sarjak Chakravarti, Snehal S. Patel, Pooja Lakhamje, Murari Gurjar, Vikram Gota, Beena G. Singh, Amit Kunwar. Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugationInternational Journal of Pharmaceutics 2020; 586: 119522 doi: 10.1016/j.ijpharm.2020.119522
9
Jinhee Kim, Hye-Youn Kim, Suntaek Hong, Sarah Shin, Young Ah Kim, No Soo Kim, Ok-Sun Bang. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX modelBiomedicine & Pharmacotherapy 2019; 116: 108987 doi: 10.1016/j.biopha.2019.108987
10
Erika Cecchin, Elena De Mattia, Fabrizio Ecca, Giuseppe Toffoli. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementationDrug Resistance Updates 2018; 39: 18 doi: 10.1016/j.drup.2018.07.001
11
Eman E. Nasr, Amany S. Mostafa, Magda A. A. El‐Sayed, Mohammed A. M. Massoud. Design, synthesis, and docking study of new quinoline derivatives as antitumor agentsArchiv der Pharmazie 2019; 352(7): 1800355 doi: 10.1002/ardp.201800355
12
Alexandra Zakharenko, Olga Luzina, Olga Koval, Dmitry Nilov, Irina Gushchina, Nadezhda Dyrkheeva, Vytas Švedas, Nariman Salakhutdinov, Olga Lavrik. Tyrosyl-DNA Phosphodiesterase 1 Inhibitors: Usnic Acid Enamines Enhance the Cytotoxic Effect of CamptothecinJournal of Natural Products 2016; 79(11): 2961 doi: 10.1021/acs.jnatprod.6b00979
13
Madhumita Roy, Amitava Datta. Cancer Genetics and Therapeutics2019; : 165 doi: 10.1007/978-981-13-9471-3_7
14
Ayako Tsuboya, Ken-ichi Fujita, Yutaro Kubota, Hiroo Ishida, Iori Taki-Takemoto, Daisuke Kamei, Shinichi Iwai, Yasutsuna Sasaki. Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancerInternational Journal of Clinical Oncology 2019; 24(2): 222 doi: 10.1007/s10147-018-1347-7
15
Susan J. Zunino, David H. Storms. Resveratrol-3-O-glucuronide and resveratrol-4′-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecinOncology Letters 2017; 14(2): 2517 doi: 10.3892/ol.2017.6392
16
Chen Zhang, Catherine Hemmert, Heinz Gornitzka, Olivier Cuvillier, Ming Zhang, Raymond Wai-Yin Sun. Cationic and Neutral N -Heterocyclic Carbene Gold(I) Complexes: Cytotoxicity, NCI-60 Screening, Cellular Uptake, Inhibition of Mammalian Thioredoxin Reductase, and Reactive Oxygen Species FormationChemMedChem 2018; 13(12): 1218 doi: 10.1002/cmdc.201800181
17
Qiao Yijie, Wang Xuejun, Xin Yuanyao, Nian Yongqiong, Yang Jianxin, Duan Yabin, Li Xiangyang. Effect of X‐ray irradiation on pharmacokinetics of irinotecan hydrochloride and expression of CES 1 and CYP 3A1 in rats Fundamental & Clinical Pharmacology 2019; 33(5): 558 doi: 10.1111/fcp.12456
18
Andrea Idili, Netzahualcóyotl Arroyo-Currás, Kyle L. Ploense, Andrew T. Csordas, Masayasu Kuwahara, Tod E. Kippin, Kevin W. Plaxco. Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living bodyChemical Science 2019; 10(35): 8164 doi: 10.1039/C9SC01495K
19
Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low. The Roles of Common Variation and Somatic Mutation in Cancer PharmacogenomicsOncology and Therapy 2019; 7(1): 1 doi: 10.1007/s40487-018-0090-6
20
Abdel B. Halim. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry2019; : 41 doi: 10.1016/B978-0-12-816121-0.00003-9
21
Nikolaos Tsakiris, Malamatenia Papavasileiou, Elia Bozzato, Alessandra Lopes, Arnaud M. Vigneron, Véronique Préat. Combinational drug-loaded lipid nanocapsules for the treatment of cancerInternational Journal of Pharmaceutics 2019; 569: 118588 doi: 10.1016/j.ijpharm.2019.118588
22
Xiang Li, Ting Liang, Si‐Si Chen, Meng Wang, Rui Wang, Kai Li, Ji‐Chang Wang, Chong‐Wen Xu, Ning Du, Sida Qin, Hong Ren. Matrine suppression of self‐renewal was dependent on regulation of LIN28A/Let‐7 pathway in breast cancer stem cellsJournal of Cellular Biochemistry 2020; 121(3): 2139 doi: 10.1002/jcb.29396
23
Jin Wang, Li Shao, Chong-Zhi Wang, Hong-Hao Zhou, Chun-Su Yuan, Wei-Hua Huang. Synergetic Inhibition of Human Colorectal Cancer Cells by Combining Polyyne-Enriched Fraction from Oplopanax elatus and IrinotecanNutrition and Cancer 2019; 71(3): 472 doi: 10.1080/01635581.2018.1516788
24
Thaise Boeing, Priscila Souza, Silvia Speca, Lincon Bordignon Somensi, Luisa Nathália Bolda Mariano, Benhur Judah Cury, Mariana Ferreira dos Anjos, Nara Lins Meira Quintão, Laurent Dubuqoy, Pierre Desreumax, Luisa Mota Silva, Sérgio Faloni Andrade. Luteolin prevents irinotecan‐induced intestinal mucositis in mice through antioxidant and anti‐inflammatory propertiesBritish Journal of Pharmacology 2020; 177(10): 2393 doi: 10.1111/bph.14987
25
Lucia Scarabel, Marica Garziera, Sara Fortuna, Fioretta Asaro, Giuseppe Toffoli, Silvano Geremia. Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategyScientific Reports 2020; 10(1) doi: 10.1038/s41598-020-65424-z
26
A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez. Current status of nanomedicine in the chemotherapy of breast cancerCancer Chemotherapy and Pharmacology 2019; 84(4): 689 doi: 10.1007/s00280-019-03910-6
27
Takashi Higuchi, Kentaro Miyake, Hiromichi Oshiro, Norihiko Sugisawa, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Sant P. Chawla, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse modelBiochemical and Biophysical Research Communications 2019; 513(2): 326 doi: 10.1016/j.bbrc.2019.03.191
28
Iera Hernandez-Unzueta, Aitor Benedicto, Elvira Olaso, Eduardo Sanz, Cristina Viera, Beatriz Arteta, Joana Márquez. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liverOncology Letters 2017; 13(6): 4002 doi: 10.3892/ol.2017.6016
29
Jiali Dai, Yuetong Chen, Yang Gong, Jingsun Wei, Xiaowen Cui, Hualin Yu, Wenjing Zhao, Dongying Gu, Jinfei Chen. The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancerMedicine 2019; 98(39): e17384 doi: 10.1097/MD.0000000000017384
30
Ana Lucić Vrdoljak, Nino Fuchs, Anja Mikolić, Suzana Žunec, Irena Brčić Karačonji, Andreja Jurič, Ljerka Prester, Vedran Micek, Marijana Neuberg, Samir Čanović, Gordan Mršić, Nevenka Kopjar. Irinotecan and Δ9-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity MarkersMolecules 2018; 23(6): 1332 doi: 10.3390/molecules23061332
31
Zhiyu Wang, Aimin Zang, Yaning Wei, Lin An, Dan Hong, Yan Shi, Jingnan Zhang, Shenyong Su, Guotao Fang. <p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>Drug Design, Development and Therapy 2020; : 1095 doi: 10.2147/DDDT.S230306
32
Myriam Mérarchi, Gautam Sethi, Lu Fan, Srishti Mishra, Frank Arfuso, Kwang Ahn. Molecular Targets Modulated by Fangchinoline in Tumor Cells and Preclinical ModelsMolecules 2018; 23(10): 2538 doi: 10.3390/molecules23102538
33
Elena De Mattia, Erika Cecchin, Marcella Montico, Adrien Labriet, Chantal Guillemette, Eva Dreussi, Rossana Roncato, Alessia Bignucolo, Angela Buonadonna, Mario D’Andrea, Luigi Coppola, Sara Lonardi, Eric Lévesque, Derek Jonker, Félix Couture, Giuseppe Toffoli. Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer PatientsFrontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.00367
34
Philip Emmerich, Linda Clipson, Dustin A. Deming. Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical ImplicationsCurrent Colorectal Cancer Reports 2017; 13(4): 334 doi: 10.1007/s11888-017-0374-5
35
Danjun Wu, Lixi Zhu, Yi Li, Huiying Wang, Shumin Xu, Xueling Zhang, Rui Wu, Gensheng Yang. Superparamagnetic chitosan nanocomplexes for colorectal tumor-targeted delivery of irinotecanInternational Journal of Pharmaceutics 2020; 584: 119394 doi: 10.1016/j.ijpharm.2020.119394
36
Xue Zhang, Jia-Fu Yin, Jiao Zhang, Shu-Jia Kong, Hong-Yin Zhang, Xue-Mei Chen. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysisCancer Chemotherapy and Pharmacology 2017; 80(1): 135 doi: 10.1007/s00280-017-3344-3
37
Pieter H. du Preez, Kelly Breeds, N. Francois V. Burger, Hendrik W. Swiegers, J. Christoff Truter, Anna-Maria Botha. DNA Methylation and Demethylation Are Regulated by Functional DNA Methyltransferases and DnTET Enzymes in Diuraphis noxiaFrontiers in Genetics 2020; 11 doi: 10.3389/fgene.2020.00452
38
Yifeng Qin, An Kang, Guisheng Zhou, Huan Wang, Wei Wei, Yujie Cao, Yanyan Chen, Jing Wang, Yajun Shi, Yuping Tang, Jianqin Jiang. Carboxylesterase and UDP-glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra-performance liquid chromatography-mass spectrometry analysisBiomedical Chromatography 2018; 32(10): e4320 doi: 10.1002/bmc.4320
39
Adrien Labriet, Éric Lévesque, Erika Cecchin, Elena De Mattia, Lyne Villeneuve, Michèle Rouleau, Derek Jonker, Félix Couture, David Simonyan, Eric P. Allain, Angela Buonadonna, Mario D’Andrea, Giuseppe Toffoli, Chantal Guillemette. Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patientsScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-49477-3
40
Michèle Boisdron-Celle, Jean Philippe Metges, Olivier Capitain, Antoine Adenis, Jean Luc Raoul, Thierry Lecomte, You Heng Lam, Roger Faroux, Claude Masliah, Anne Lise Poirier, Virginie Berger, Alain Morel, Erick Gamelin. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensificationSeminars in Oncology 2017; 44(1): 24 doi: 10.1053/j.seminoncol.2017.02.007
41
Elke Cario. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicityCurrent Opinion in Supportive and Palliative Care 2016; 10(2): 157 doi: 10.1097/SPC.0000000000000202
42
Shan Lu, Obinna N. Obianom, Yong Ai. Novel hybrids derived from aspirin and chalcones potently suppress colorectal cancer in vitro and in vivoMedChemComm 2018; 9(10): 1722 doi: 10.1039/C8MD00284C
43
Dimitra-Ioanna Lampropoulou, Gerasimos Aravantinos, Hector Katifelis, Foivos Lazaris, Konstantinos Laschos, Theodosios Theodosopoulos, Christos Papadimitriou, Maria Gazouli. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancerCancer Biomarkers 2019; 25(2): 213 doi: 10.3233/CBM-182383
44
Elena De Mattia, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli. Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicinePharmacogenomics 2016; 17(14): 1547 doi: 10.2217/pgs-2016-0095
45
Tetsuya Hamaguchi, Akihito Tsuji, Kensei Yamaguchi, Koji Takeda, Hiroyuki Uetake, Taito Esaki, Kenji Amagai, Daisuke Sakai, Hideo Baba, Masami Kimura, Yasuhiro Matsumura, Tetsuji Tsukamoto. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patientsCancer Chemotherapy and Pharmacology 2018; 82(6): 1021 doi: 10.1007/s00280-018-3693-6
46
Christine M. Heske, Arnulfo Mendoza, Leah D. Edessa, Joshua T. Baumgart, Sunmin Lee, Jane Trepel, David A. Proia, Len Neckers, Lee J. Helman. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaOncotarget 2016; 7(40): 65540 doi: 10.18632/oncotarget.11869
47
Adrien Labriet, Elena De Mattia, Erika Cecchin, Éric Lévesque, Derek Jonker, Félix Couture, Angela Buonadonna, Mario D’Andrea, Lyne Villeneuve, Giuseppe Toffoli, Chantal Guillemette. Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27LFrontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00712
48
Sergio C. Chai, William C. Wright, Taosheng Chen. Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancerMedicinal Research Reviews 2020; 40(3): 1061 doi: 10.1002/med.21648
49
Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou, Yong Tang. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancerCancer Chemotherapy and Pharmacology 2016; 78(1): 119 doi: 10.1007/s00280-016-3057-z
50
Yihan Wu, Di Wang, Xiaoqin Yang, Chaomei Fu, Liang Zou, Jinming Zhang. Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in miceBiomedicine & Pharmacotherapy 2019; 109: 2252 doi: 10.1016/j.biopha.2018.11.095
51
Fabio Gosetti, Masho Hilawie Belay, Emilio Marengo, Elisa Robotti. Development and validation of a UHPLC-MS/MS method for the identification of irinotecan photodegradation products in water samplesEnvironmental Pollution 2020; 256: 113370 doi: 10.1016/j.envpol.2019.113370
52
Ruipu Sun, Ying Ying, Zhimin Tang, Ting Liu, Fuli Shi, Huixia Li, Taichen Guo, Shibo Huang, Ren Lai. The Emerging Role of the SLCO1B3 Protein in Cancer ResistanceProtein & Peptide Letters 2019; 27(1): 17 doi: 10.2174/0929866526666190926154248
53
Ming-Hsien Lin, Chi-Feng Hung, Ching-Yun Hsu, Zih-Chan Lin, Jia-You Fang. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiencyFuture Medicinal Chemistry 2019; 11(16): 2131 doi: 10.4155/fmc-2018-0388
54
Tahia K. Mohamed, Rasha Z. Batran, Samia A. Elseginy, Mamdouh M. Ali, Abeer E. Mahmoud. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosisBioorganic Chemistry 2019; 85: 253 doi: 10.1016/j.bioorg.2018.12.040
55
Boah Lee, Jeong A. Min, Abdullateef Nashed, Sang-Ok Lee, Jae Cheal Yoo, Seung-Wook Chi, Gwan-Su Yi. A novel mechanism of irinotecan targeting MDM2 and Bcl-xLBiochemical and Biophysical Research Communications 2019; 514(2): 518 doi: 10.1016/j.bbrc.2019.04.009
56
Riccardo Rampado, Sara Crotti, Paolo Caliceti, Salvatore Pucciarelli, Marco Agostini. Nanovectors Design for Theranostic Applications in Colorectal CancerJournal of Oncology 2019; 2019: 1 doi: 10.1155/2019/2740923
57
Shi-Yu Liu, Ren-Yu Qu, Rong-Rong Li, Yao-Chao Yan, Yao Sun, Wen-Chao Yang, Guang-Fu Yang. An Activity-Based Fluorogenic Probe Enables Cellular and in Vivo Profiling of Carboxylesterase IsozymesAnalytical Chemistry 2020;  doi: 10.1021/acs.analchem.0c01554
58
Shan Lu, Obinna N. Obianom, Yong Ai. Novel cinnamaldehyde-based aspirin derivatives for the treatment of colorectal cancerBioorganic & Medicinal Chemistry Letters 2018; 28(17): 2869 doi: 10.1016/j.bmcl.2018.07.032
59
Yu Hou, Xiaoni Ai, Lin Zhao, Zhao Gao, Yujiang Wang, Yingyuang Lu, Pengfei Tu, Yong Jiang. An integrated biomimetic array chip for high-throughput co-culture of liver and tumor microtissues for advanced anticancer bioactivity screeningLab on a Chip 2020;  doi: 10.1039/D0LC00288G
60
Larissa Costa de Almeida, Anelize Bauermeister, Paula Rezende-Teixeira, Evelyne Alves dos Santos, Luiz Alberto Beraldo de Moraes, João Agostinho Machado-Neto, Leticia Veras Costa-Lotufo. Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cellsBiochemical Pharmacology 2019; 168: 38 doi: 10.1016/j.bcp.2019.06.016
61
Daniel C. Pan, Vinu Krishnan, Alyssa K. Salinas, Jayoung Kim, Tao Sun, Sagi Ravid, Kevin Peng, Debra Wu, Md Nurunnabi, Jeffery A. Nelson, Zachary Niziolek, Junling Guo, Samir Mitragotri. Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer Bioengineering & Translational Medicine 2020;  doi: 10.1002/btm2.10166
62
Jia-Nan Li, Yun-Feng Cao, Rong-Rong He, Guang-Bo Ge, Bin Guo, Jing-Jing Wu. Evidence for Shikonin acting as an active inhibitor of human carboxylesterases 2: Implications for herb-drug combinationPhytotherapy Research 2018; 32(7): 1311 doi: 10.1002/ptr.6062
63
Anne Kauffels, Marie Kitzmüller, Andrea Gruber, Hannah Nowack, Hanibal Bohnenberger, Melanie Spitzner, Anja Kuthning, Thilo Sprenger, Martin Czejka, Michael Ghadimi, Jens Sperling. Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastasesClinical & Experimental Metastasis 2019; 36(1): 57 doi: 10.1007/s10585-019-09954-5
64
Chen Shaojun, Hua Li, Huang Haixin, Li Guisheng. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancerCancer Biology & Therapy 2018; 19(3): 153 doi: 10.1080/15384047.2017.1414754
65
Sylvia Chen, Natalia Sutiman, Clara Zhenxian Zhang, Yingnan Yu, Shirley Lam, Chiea Chuen Khor, Balram Chowbay. Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative reviewDrug Metabolism Reviews 2016; 48(4): 502 doi: 10.1080/03602532.2016.1226896
66
Tatyana Khomenko, Alexandra Zakharenko, Tatyana Odarchenko, Homayon John Arabshahi, Victoriya Sannikova, Olga Zakharova, Dina Korchagina, Jóhannes Reynisson, Konstantin Volcho, Nariman Salakhutdinov, Olga Lavrik. New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moietiesBioorganic & Medicinal Chemistry 2016; 24(21): 5573 doi: 10.1016/j.bmc.2016.09.016